Model Number 3CX*FX25RWC |
Device Problem
Material Discolored (1170)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 11/04/2021 |
Event Type
malfunction
|
Event Description
|
The user facility reported to terumo cardiovascular that prior to cardiopulmonary bypass, during non clinical activity, black spot was noted in the material.No patient involvement.
|
|
Manufacturer Narrative
|
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.(b)(4).
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on may 04, 2017.Upon further investigation of the reported event, the following information is new and/or changed: d4 (additional device information - added expiration date); g3 (date received by manufacturer) ; g6 (indication that this is a follow-up report) ; h2 (follow-up due to additional information and device evaluation) ; h3 (device evaluated by manufacturer) ; h4 (device manufacture date); h6 (identification of evaluation codes 10, 11, 3331, 4238, 25).Type of investigation 1#: 10 - testing of actual/suspected device.Type of investigation 2#: 11 - testing of device from same lot/batch retained by manufacturer.Type of investigation 3#: 3331 - analysis of production records.Investigation findings: 4238 - contamination of environment by device.Investigation conclusions: 25 - cause traced to manufacturing.The affected sample was inspected and confirmed a mark in the reservoir.Further inspection revealed that the marking is embedded within the plastic.A representative retention sample was inspected to show no anomalies with the device, including no foreign matter.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on november 23, 2021.Upon further investigation of the reported event, the following information is new and/or changed: d9 (device availability - added date returned to manufacturer) g3 (date received by manufacturer) g6 (indication that this is a follow-up report) h2 (follow-up due to additional information) h3 (device evaluation anticipated by manufacturer - a second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11.).All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Search Alerts/Recalls
|
|